Norah A. Almutairi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Norah A. Almutairi has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Manoj Sivan
Academic Department of Rehabilitation Medicine, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds LS2 9JT, UK
3 shared publications - Darren Charles Greenwood
Leeds Institute for Cardiovascular and Metabolic Medicine, School of Medicine, University of Leeds , Leeds
2 shared publications - Belinda Godfrey
Leeds Community Healthcare, Leeds LS11 0DL, UK
1 shared publication - Julia Barr
Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds LS7 4SA, UK
1 shared publication - Lowri Marsden
Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds LS7 4SA, UK
1 shared publication Maha M. Almarwani
Health Rehabilitation Sciences Department, College of Applied Medical Sciences, King Saud University, Riyadh, Saudi Arabia
1 shared publication
Latest Publications
- Open Access
- 10 November 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (22) , 8792
Detecting and Characterising Autonomic Dysfunction in Chronic Musculoskeletal Pain: A Cross-Sectional Comparison with Pain-Free Controls
Background/Objectives: Autonomic dysfunction is increasingly being reported in adults with chronic musculoskeletal pain (CMP). We assessed subjective and objective markers of dysautonomia in a CMP population. Methods: We recruited 100 adults with confirmed inflammatory or non-inflammatory musculoskeletal diagnoses associated with CMP attending rheumatology and orthopaedic clinics, and age- and sex-matched 56 pain-free controls. Participants completed the Composite Autonomic Symptom Score 31 (COMPASS-31) dysautonomia scale, Brief Pain Inventory and Hospital Anxiety and Depression Scale, and a 10 min Lean Test (LT). A positive LT was defined as either orthostatic hypotension (OH) or Postural Tachycardia Syndrome (PoTS), determined by standard thresholds for heart-rate and blood-pressure changes as defined in the existing literature. Results: Autonomic symptom burden was identified in 83% of CMP participants at the conventional threshold (COMPASS-31 score ≥ 17) and 72% at the higher threshold (≥28.67) compared with 11% and 0% of controls. Median COMPASS-31 was 41.8 (IQR 25.8–54.8) in CMP and 2.9 (0.4–10.8) in controls (median difference 35.1, 95%CI 29.6–40.4, p < 0.001). A positive Lean Test occurred in 28% of CMP participants (12% PoTS; 16% OH) and 5% of controls (OR 6.80, 95% CI 1.94–36.8, p = 0.001). In the CMP participants, COMPASS-31 discriminated poorly between a positive and negative LT (AUC 0.55, 95%CI 0.42–0.67). No statistically significant difference was detected between inflammatory and non-inflammatory conditions in this sample, on subjective (73% vs. 71%) and objective (27% vs. 29%) assessment. Conclusions: Dysautonomia is common in CMP. The poor discrimination of COMPASS-31 against objective Lean Test findings (AUC 0.55) indicates that subjective and objective measures provide complementary information, supporting consideration of both in autonomic assessment.
- 10 November 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (22) , 8792
Open AccessDetecting and Characterising Autonomic Dysfunction in Chronic Musculoskeletal Pain: A Cross-Sectional Comparison with Pain-Free Controls
Background/Objectives: Autonomic dysfunction is increasingly being reported in adults with chronic musculoskeletal pain (CMP). We assessed subjective and objective markers of dysautonomia in a CMP population. Methods: We recruited 100 adults with confirmed inflammatory or non-inflammatory musculoskeletal diagnoses associated with CMP attending rheumatology and orthopaedic clinics, and age- and sex-matched 56 pain-free controls. Participants completed the Composite Autonomic Symptom Score 31 (COMPASS-31) dysautonomia scale, Brief Pain Inventory and Hospital Anxiety and Depression Scale, and a 10 min Lean Test (LT). A positive LT was defined as either orthostatic hypotension (OH) or Postural Tachycardia Syndrome (PoTS), determined by standard thresholds for heart-rate and blood-pressure changes as defined in the existing literature. Results: Autonomic symptom burden was identified in 83% of CMP participants at the conventional threshold (COMPASS-31 score ≥ 17) and 72% at the higher threshold (≥28.67) compared with 11% and 0% of controls. Median COMPASS-31 was 41.8 (IQR 25.8–54.8) in CMP and 2.9 (0.4–10.8) in controls (median difference 35.1, 95%CI 29.6–40.4, p < 0.001). A positive Lean Test occurred in 28% of CMP participants (12% PoTS; 16% OH) and 5% of controls (OR 6.80, 95% CI 1.94–36.8, p = 0.001). In the CMP participants, COMPASS-31 discriminated poorly between a positive and negative LT (AUC 0.55, 95%CI 0.42–0.67). No statistically significant difference was detected between inflammatory and non-inflammatory conditions in this sample, on subjective (73% vs. 71%) and objective (27% vs. 29%) assessment. Conclusions: Dysautonomia is common in CMP. The poor discrimination of COMPASS-31 against objective Lean Test findings (AUC 0.55) indicates that subjective and objective measures provide complementary information, supporting consideration of both in autonomic assessment.
- Open Access
- 25 March 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (7) , 2510
Testing a Personalised Dysautonomia Management Protocol in Patients with Orthostatic Intolerance and a Diagnosis of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome or Long COVID
Background/Objectives: Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) and Long COVID (LC) are complex multisystem conditions with significant functional disability. Many patients experience symptoms of orthostatic intolerance, which can be captured in some cases as Orthostatic Hypotension (OH) or Postural orthostatic Tachycardia Syndrome (PoTS) on objective testing. Conservative treatments are recommended for first-line symptom management, but there is a lack of efficacy evidence. This study aims to assess the feasibility of an 8-week clinically supervised, personalised Dysautonomia Management Protocol (DMP) in a cohort of ME/CFS and LC patients with subjective and objective evidence of orthostatic intolerance (dysautonomia). Methods: ME/CFS and LC patients with objective dysautonomia on the 10 min active Lean Test (LT) were recruited to an 8-week DMP, with interventions introduced cumulatively every two weeks. Interventions included increasing daily fluid intake to 3 litres and salt intake to 10 g, pacing to avoid crashes and calf activation. Baseline and weekly data collection included the LT, Composite Autonomic Symptom Score questionnaire (COMPASS-31) and Yorkshire Rehabilitation Scale (YRS). Results: Sixteen participants completed the 8-week program, five discontinued during the program, and one was withdrawn following a severe crash. The COMPASS-31 improved by 7.7 points from week 1 to week 8 (p = 0.045), with a medium Cohen’s d effect size of 0.55. For the same period, there was a non-significant (p = 0.16) improvement in the YRS symptom severity score by 2 points. Comparing the final two weeks of the program with the first two weeks, mean heart rate during the LT decreased by 4.8 beats per minute (p = 0.032), with a medium Cohen’s d effect size of 0.44. Adherence to the interventions was highly variable, with none of the patients able to fully employ all four recommendations. Conclusions: The results suggest that targeted conservative interventions could influence autonomic function and symptom reduction. However, the magnitude of change was limited, and statistical significance might not necessarily relate to a clinically significant improvement in symptoms.
- 25 March 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (7) , 2510
Open AccessTesting a Personalised Dysautonomia Management Protocol in Patients with Orthostatic Intolerance and a Diagnosis of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome or Long COVID
Background/Objectives: Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) and Long COVID (LC) are complex multisystem conditions with significant functional disability. Many patients experience symptoms of orthostatic intolerance, which can be captured in some cases as Orthostatic Hypotension (OH) or Postural orthostatic Tachycardia Syndrome (PoTS) on objective testing. Conservative treatments are recommended for first-line symptom management, but there is a lack of efficacy evidence. This study aims to assess the feasibility of an 8-week clinically supervised, personalised Dysautonomia Management Protocol (DMP) in a cohort of ME/CFS and LC patients with subjective and objective evidence of orthostatic intolerance (dysautonomia). Methods: ME/CFS and LC patients with objective dysautonomia on the 10 min active Lean Test (LT) were recruited to an 8-week DMP, with interventions introduced cumulatively every two weeks. Interventions included increasing daily fluid intake to 3 litres and salt intake to 10 g, pacing to avoid crashes and calf activation. Baseline and weekly data collection included the LT, Composite Autonomic Symptom Score questionnaire (COMPASS-31) and Yorkshire Rehabilitation Scale (YRS). Results: Sixteen participants completed the 8-week program, five discontinued during the program, and one was withdrawn following a severe crash. The COMPASS-31 improved by 7.7 points from week 1 to week 8 (p = 0.045), with a medium Cohen’s d effect size of 0.55. For the same period, there was a non-significant (p = 0.16) improvement in the YRS symptom severity score by 2 points. Comparing the final two weeks of the program with the first two weeks, mean heart rate during the LT decreased by 4.8 beats per minute (p = 0.032), with a medium Cohen’s d effect size of 0.44. Adherence to the interventions was highly variable, with none of the patients able to fully employ all four recommendations. Conclusions: The results suggest that targeted conservative interventions could influence autonomic function and symptom reduction. However, the magnitude of change was limited, and statistical significance might not necessarily relate to a clinically significant improvement in symptoms.
- Open Access
- 18 March 2026
- Published by Oxford University Press (OUP) in Rheumatology Advances in Practice
- Vol. 10 (2)
The prevalence of dysautonomia in chronic musculoskeletal pain: a systematic review and meta-analysis
Objectives: Several chronic musculoskeletal disorders are characterized by pain, fatigue, dizziness and other associated symptoms that may be related to autonomic dysfunction. The aim of this review was to estimate the prevalence of autonomic dysfunction in chronic musculoskeletal pain conditions. Methods: MEDLINE and Embase were searched through 4 October 2024 for all peer-reviewed studies of dysautonomia in adult musculoskeletal conditions. Risk of bias was assessed using an adapted Newcastle–Ottawa Scale. The prevalence of dysautonomia and relative risk compared with healthy controls were estimated using random effects meta-analysis. Results: A total of 17 studies (13 fibromyalgia, 3 Ehlers–Danlos syndrome, 1 rheumatoid arthritis) were identified, including 1003 participants with musculoskeletal pain and 417 healthy controls. In people with chronic musculoskeletal pain, the pooled prevalence of dysautonomia was 64% (95% CI 51, 76; I2 = 93%), more than twice as likely as healthy controls [pooled risk ratio 2.28 (95% CI 1.51, 3.45); I2 = 24%). Most studies objectively assessed the neurocardiovascular system. Conclusion: The high prevalence of dysautonomia in patients with chronic musculoskeletal painful conditions illustrates the association between dysautonomia and chronic pain, suggesting regular screening for dysautonomia is warranted for all patients with chronic musculoskeletal pain.
- 18 March 2026
- Published by Oxford University Press (OUP) in Rheumatology Advances in Practice
- Vol. 10 (2)
Open AccessThe prevalence of dysautonomia in chronic musculoskeletal pain: a systematic review and meta-analysis
Objectives: Several chronic musculoskeletal disorders are characterized by pain, fatigue, dizziness and other associated symptoms that may be related to autonomic dysfunction. The aim of this review was to estimate the prevalence of autonomic dysfunction in chronic musculoskeletal pain conditions. Methods: MEDLINE and Embase were searched through 4 October 2024 for all peer-reviewed studies of dysautonomia in adult musculoskeletal conditions. Risk of bias was assessed using an adapted Newcastle–Ottawa Scale. The prevalence of dysautonomia and relative risk compared with healthy controls were estimated using random effects meta-analysis. Results: A total of 17 studies (13 fibromyalgia, 3 Ehlers–Danlos syndrome, 1 rheumatoid arthritis) were identified, including 1003 participants with musculoskeletal pain and 417 healthy controls. In people with chronic musculoskeletal pain, the pooled prevalence of dysautonomia was 64% (95% CI 51, 76; I2 = 93%), more than twice as likely as healthy controls [pooled risk ratio 2.28 (95% CI 1.51, 3.45); I2 = 24%). Most studies objectively assessed the neurocardiovascular system. Conclusion: The high prevalence of dysautonomia in patients with chronic musculoskeletal painful conditions illustrates the association between dysautonomia and chronic pain, suggesting regular screening for dysautonomia is warranted for all patients with chronic musculoskeletal pain.